Please assess the completion status of the following clinical trial:

Trial Title: Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate Stones

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Has hyperuricosuria, defined as a daily urine uric acid excretion greater than 700 mg as measured by 24-hour urine collection prior to randomization.~* Has at least one calcium oxalate stone greater than or equal to 3 mm in its longest in-plane diameter, identified by Multiple Detector Computated Tomography prior to randomization.~* Has a recent (within the previous 5 years) history of renal stones prior to screening.~Exclusion Criteria:~* Has gout, secondary hyperuricemia or has experienced a gout flare.~* Has a history of xanthinuria.~* Has received allopurinol or probenecid within 2 years prior to randomization.~* Has received febuxostat.~* Has alanine aminotransferase and/or aspartate aminotransferase values greater than 2.0 times the upper limit of normal at the Screening Visit.~* Has an abnormal serum calcium level at the Screening Visit.~* Has a significant medical condition and/or conditions that would interfere with the treatment, safety or compliance with the protocol according to the judgment of the Investigator.~* Has a history of drug abuse or a history of alcohol abuse within 5 years prior to the Screening Visit.~* Participant's measured creatinine clearance is less than 30 mL/min at the Screening Visit.~* Has hypercalciuria at Screening, while on a regular unrestricted diet, defined as urinary excretion of:~  * greater than 250 mg of calcium/24-hour for females of body weight less than 62.5 kg; OR~ * greater than 300 mg calcium/24-hour for males of body weight less than 75 kg; OR~ * greater than 4 mg calcium/kg/24-hour for males of body weight greater than or equal 75 kg and females of body weight greater than or equal 62.5 kg.~EXCLUDED MEDICATIONS:~* Febuxostat, allopurinol, probenecid.~* Salicylates (chronic use of aspirin ≤325 mg/day is allowed).~* Azathioprine.~* Mercaptopurine.~* Theophylline.~* Colchicine.~* Pyrazinamide.~* Sulfamethoxazole/trimethoprim.~* Losartan.~The following restrictions also apply during the study:~* Long-term use (more than 4 continuous weeks) of prescription or over-the-counter nonsterioidal anti-inflammatory drugs or cyclooxygenase-2 inhibitors.~* If receiving diuretics, participant must have been on a stable dose for at least 30 days prior to screening. No changes in dosage are allowed during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Febuxostat (Type: EXPERIMENTAL): Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.
- Allopurinol (Type: ACTIVE_COMPARATOR): Allopurinol 200mg or 300mg (determined by kidney function), capsules, orally, once daily for up to 6 months.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo-matching capsules, orally, once daily for up to 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).